Hologic Completes Acquisition of Biotheranostics | 合法醫療器材資訊網

2021年1月5日 — “Together with the Biotheranostics team, we can leverage our commercial capabilities and expertise in molecular diagnostics automation to ... Read More

Biotheranostics develops and markets two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index™ (BCI) and ... Read More

2021年1月6日 — Hologic (HOLX) said that Biotheranostics provides molecular diagnostic ... submitted an application for an initial public offering (IPO) on China's ... Read More

The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy. Read More

2016年1月21日 — BioTheranostics will use the money from the financing round to grow its ... Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With ... Read More

dr. miriam bloch biotheranostics. Miriam J. Bloch, MD | Laboratory Director. Read More

2020年12月8日 — Treuner et alCatherine Schnabel, Biotheranostics' Chief Scientific Officer ... China Blocks Didi From App Stores Days After Mega U.S. IPO. Read More

Biotheranostics is a commercial-stage molecular diagnostics company that support physicians in the treatment of cancer patients. Read More

2021年1月5日 — “Together with the Biotheranostics team, we can leverage our commercial capabilities and expertise in molecular diagnostics automation to ... Read More

2021年1月5日 — Hologic said that Biotheranostics' PCR-based gene expression tests have ... Sophia Genetics Files for $100M IPO, Inks Cancer Data Deal With ... Read More